


Int. Appln. No.: PCT/US04/024052
 US Appln. No.: 10/566,235
 US Filing Date: Jan. 27, 2006
 Case No.: 21482YP
 Page No.: 2

RECEIVED
 CENTRAL FAX CENTER

MAY 21 2007

Listing of Claims:

1. (original) A compound of the formula I:



or a pharmaceutically acceptable salt thereof; wherein
 each n is independently 0, 1, or 2;

Ar is phenyl substituted with one to five R³ substituents;

R¹ is selected from the group consisting of
 hydrogen,

C₁₋₁₀ alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁₋₆ alkoxy, carboxy, C₁₋₆ alkyloxycarbonyl, and phenyl-C₁₋₃ alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,

(CH₂)_n-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, CN, hydroxy, R², OR², NHSO₂R², NR²SO₂R², SO₂R², CO₂H, and C₁₋₆ alkyloxycarbonyl,

(CH₂)_n-heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, C₁₋₆ alkyl, and C₁₋₆ alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

(CH₂)_n-heterocyclyl, wherein heterocyclyl is unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, C₁₋₆ alkyl, and C₁₋₆ alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

Int. Appln. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 3

$(CH_2)_n$ -C₃₋₆ cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C₁₋₆ alkyl, and C₁₋₆ alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; and

wherein any methylene (CH₂) carbon atom in $(CH_2)_n$ is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C₁₋₄ alkyl unsubstituted or substituted with one to five halogens;

each R³ is independently selected from the group consisting of
hydrogen,
halogen,
cyano,
hydroxy,
C₁₋₆ alkyl, unsubstituted or substituted with one to five halogens,
C₁₋₆ alkoxy, unsubstituted or substituted with one to five halogens,
carboxy,
alkoxycarbonyl,
amino,
NHR²,
NR²R²,
NHSO₂R²,
NR²SO₂R²,
NHCOR²,
NR²COR²,
• NHCO₂R²,
NR²CO₂R²,
SO₂R²,
SO₂NH₂,
SO₂NHR², and
SO₂NR²R²;

each R² is independently C₁₋₆ alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, CO₂H, and C₁₋₆ alkyloxycarbonyl;

Int. Appn. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 4

R4, R6, and R10 are each independently selected from the group consisting of:
hydrogen,
cyano,
carboxy,
C1-6 alkyloxycarbonyl,

C1-10 alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C1-6 alkoxy, carboxy,

C1-6 alkyloxycarbonyl, and phenyl-C1-3 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,

(CH₂)_n-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C1-6 alkyl, and C1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

(CH₂)_n-heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, C1-6 alkyl, and C1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

(CH₂)_n-heterocyclyl, wherein heterocyclyl is unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, C1-6 alkyl, and C1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

(CH₂)_n-C3-6 cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C1-6 alkyl, and C1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

(CH₂)_nCONR¹²R¹³, wherein R¹² and R¹³ are independently selected from the group consisting of hydrogen, tetrazolyl, thiazolyl, (CH₂)_n-phenyl, (CH₂)_n-C3-6 cycloalkyl, and C1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C1-6 alkyl, and C1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; or wherein R¹² and R¹³ together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said

Int. Appln. No.: PCT/US04/024052
 US Appln. No.: 10/566,235
 US Filing Date: Jan. 27, 2006
 Case No.: 21482YP
 Page No.: 5

heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁-6 alkyl, and C₁-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;


and wherein any methylene (CH₂) carbon atom in (CH₂)_n is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C₁-4 alkyl unsubstituted or substituted with one to five halogens;

R⁸ is selected from the group consisting of halogen, hydroxy, and R⁴;

R⁵, R⁷ and R¹¹ are each independently hydrogen or C₁-6 alkyl; or wherein R⁷ and R¹ together with the nitrogen atom to which R¹ is attached form a heterocyclic ring selected from azetidine, pyrrolidine and piperidine wherein said heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁-6 alkyl, and C₁-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; and

R⁹ is selected from the group consisting of hydrogen, hydroxy, halogen, or C₁-6 alkyl; with the proviso that at least one of R⁶, R⁷, R⁸ and R⁹ is not hydrogen.

2. (original) The compound of Claim 1 of the formula Ia:



wherein the carbon atom marked with an * has the R configuration.

3. (original) The compound of Claim 1 wherein R³ is selected from the group consisting of hydrogen, fluoro, chloro, bromo, trifluoromethyl, and methyl.

4. (original) The compound of Claim 3 wherein R³ is hydrogen, chloro, or fluoro.

Int. Appln. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 6

5. (original) The compound of Claim 1 wherein R¹ is selected from the group consisting of

hydrogen,

C₁-6 alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁-6 alkoxy, carboxy, C₁-6 alkyloxycarbonyl, and phenyl-C₁-3 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens, and

(CH₂)_n-C₃-6 cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C₁-6 alkyl, and C₁-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; and

wherein any methylene (CH₂) carbon atom in (CH₂)_n is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C₁-4 alkyl unsubstituted or substituted with one to five halogens.

6. (original) The compound of Claim 5 wherein R¹ is selected from the group consisting of hydrogen, methyl, and cyclopropyl.

7. (original) The compound of Claim 6 wherein R¹ is hydrogen.

8. (original) The compound of Claim 1 wherein R⁴ is selected from the group consisting of:

hydrogen,

C₁-6 alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁-6 alkoxy, carboxy, C₁-6 alkyloxycarbonyl, and phenyl-C₁-3 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,

(CH₂)_n-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁-6 alkyl, and C₁-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

(CH₂)_n-heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, C₁-6 alkyl, and C₁-6

Int. Appln. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 7

alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

$(\text{CH}_2)_n\text{-C}_3\text{-}6$ cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, $\text{C}_{1\text{-}6}$ alkyl, and $\text{C}_{1\text{-}6}$ alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; and

wherein any methylene (CH_2) carbon atom in $(\text{CH}_2)_n$ is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and $\text{C}_{1\text{-}4}$ alkyl unsubstituted or substituted with one to five halogens.

9. (original) The compound of Claim 8 wherein R^4 is selected from the group consisting of:

hydrogen,
 CH_3 ,
 CH_2CH_3 ,
 CH_2CF_3 ,
 $\text{CH}_2(2\text{-pyridyl})$,
 CH_2Ph ,
 $\text{CH}_2(2\text{-F-Ph})$,
 $\text{CH}_2(2\text{-Me-Ph})$, and
 $\text{CH}_2(2\text{-CF}_3\text{-Ph})$.

10. (original) The compound of Claim 1 wherein R^6 is selected from the group consisting of:

hydrogen,
 $\text{C}_{1\text{-}6}$ alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, $\text{C}_{1\text{-}6}$ alkoxy, carboxy, $\text{C}_{1\text{-}6}$ alkyloxycarbonyl, and phenyl- $\text{C}_{1\text{-}3}$ alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,

$(\text{CH}_2)_n\text{-aryl}$, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, $\text{C}_{1\text{-}6}$ alkyl, and $\text{C}_{1\text{-}6}$ alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

$(\text{CH}_2)_n\text{-heteroaryl}$, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, $\text{C}_{1\text{-}6}$ alkyl, and $\text{C}_{1\text{-}6}$

Int. Appln. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 8

alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,
 $(CH_2)_n\text{-C}_3\text{-6 cycloalkyl}$, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C₁-6 alkyl, and C₁-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; and
wherein any methylene (CH_2) carbon atom in $(CH_2)_n$ is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C₁-4 alkyl unsubstituted or substituted with one to five halogens.

11. (original) The compound of Claim 10 wherein R₆ is selected from the group consisting of:

hydrogen,
C₁-6 alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁-6 alkoxy, carboxy, C₁-6 alkyloxycarbonyl, and phenyl-C₁-3 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens, and

$(CH_2)_n\text{-aryl}$, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁-6 alkyl, and C₁-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; and

wherein methylene (CH_2) carbon atom in $(CH_2)_n$ is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C₁-4 alkyl unsubstituted or substituted with one to five halogens.

12. (original) The compound of Claim 11 wherein R₆ is selected from the group consisting of:

hydrogen,
 CH_3 ,
 CH_2CH_3 ,
 CF_3 ,
 CH_2Ph , and
 $CH_2(2-F-Ph)$.

Int. Appln. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 9

13. (original) The compound of Claim 1 wherein R⁸ is selected from the group consisting of:

hydrogen,

hydroxy,

halogen, and

C₁-6 alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁-6 alkoxy, carboxy, C₁-6 alkyloxycarbonyl, and phenyl-C₁-3 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens.

14. (original) The compound of Claim 13 wherein R⁸ is hydrogen.

15. (original) The compound of Claim 1 wherein R¹⁰ is selected from the group consisting of:

hydrogen, and

C₁-6 alkyl, unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁-6 alkoxy, carboxy, C₁-6 alkyloxycarbonyl, and phenyl-C₁-3 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens.

16. (original) The compound of Claim 15 wherein R¹⁰ is hydrogen.

17. (original) The compound of Claim 1 wherein R⁵, R⁷ and R¹¹ are each independently selected from hydrogen and methyl.

18. (original) The compound of Claim 17 wherein R⁵, R⁷ and R¹¹ are hydrogen.

19. (original) The compound of Claim 1 wherein R⁹ is selected from hydrogen, halogen and methyl.

20. (original) The compound of Claim 19 wherein R⁹ is hydrogen.

21. (original) The compound of Claim 19 wherein R⁹ is methyl and R⁵, R⁷, R⁸, R¹⁰, and R¹¹ are hydrogen.

Int. Appln. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 10

22. (original) The compound of Claim 21 wherein R⁴ is selected from the group consisting of:

hydrogen,
CH₃,
CH₂CH₃,
CH₂CF₃,
CH₂(2-pyridyl),
CH₂Ph,
CH₂(2-F-Ph),
CH₂(2-Me-Ph), and
CH₂(2-CF₃-Ph).

23. (original) The compound of Claim 1 wherein R⁵, R⁷, R⁸, R⁹, R¹⁰, and R¹¹ are hydrogen, with the proviso that R⁶ is not hydrogen.

24. (original) The compound of Claim 23 wherein R⁴ is selected from the group consisting of:

hydrogen,
CH₃,
CH₂CH₃,
CH₂CF₃,
CH₂(2-pyridyl),
CH₂Ph,
CH₂(2-F-Ph),
CH₂(2-Me-Ph), and
CH₂(2-CF₃-Ph); and


R⁶ is selected from the group consisting of:

CH₃,
CH₂CH₃,
CF₃,
CH₂Ph, and
CH₂(2-F-Ph).

25. (original) The compound of Claim 24 wherein R¹ is hydrogen.

Int. Appln. No.: PCT/US04/024052
 US Appln. No.: 10/566,235
 US Filing Date: Jan. 27, 2006
 Case No.: 21482YP
 Page No.: 11

26. (original) The compound of Claim 25 wherein the stereogenic carbon atoms marked with an ** and an *** have the stereochemistry as depicted in formula Ib:



27. (original) The compound of Claim 1 wherein R⁷ and R¹ together with the nitrogen atom to which R¹ is attached form a heterocyclic ring selected from azetidine, pyrrolidine and piperidine wherein said heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁-6 alkyl, and C₁-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens.





28. (original) The compound of Claim 27 wherein R⁷ and R¹ together with the nitrogen atom to which R¹ is attached form a pyrrolidine ring.

29. (original) The compound of Claim 28 wherein R⁴ is selected from the group consisting of:





- hydrogen,
- CH₃,
- CH₂CH₃,
- CH₂CF₃,
- CH₂(2-pyridyl),
- CH₂Ph,
- CH₂(2-F-Ph),
- CH₂(2-Me-Ph), and
- CH₂(2-CF₃-Ph).

30. (original) A compound selected from the group consisting of:

Int. Appln. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 12



Int. Appn. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 13



or a pharmaceutically acceptable salt thereof.

31. (original) A pharmaceutical composition which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.

Int. Appln. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 14

32. (previously amended) A method of treating Type 2 diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.

33-34. (previously cancelled)